Economists: FDA's 'Frankenfish' review flawed

According to Canada's CBC News, Duke University economics researchers are criticising the U.S. Food and Drug Administration's review of AquaBounty's genetically modified organism, AquaAdvantage Salmon, an Atlantic salmon facsimile modified to grow twice as fast as an unaltered salmon. The Duke economists argue that the review was flawed because it was too narrow, in that it didn't look at market impacts or broad environmental impacts the new fish might have if it were approved. Among the researchers' chief concerns were understanding the affect the precocious organisms would have on the established market for salmon, and gauging the impact the increased need for feed would have on fisheries that provide fishmeal and fish oil to the farming industry. Read more, here.